港股异动|加速布局工业大麻业务美瑞健康国际续涨逾12%
格隆汇8月7日丨美瑞健康国际(2327.HK)继昨日上涨10.1%后,于今日再度上涨12.24%,报0.55港元,暂成交945万港元,最新总市值23.5亿港元。公司8月5日公告称,为了加快推进大麻制药和工业大麻产业的全球布局,公司拟投资不低于1亿港元成立工业大麻控股集团公司-瑞麻控股。同时,拟整合公司同日本龙舞在雾化技术上的资源和优势,在日本成立一家合资公司以从事CBD等大麻素雾化技术的研发和利用,推动雾化电子器械等有益健康相关产品在日本及国际市场的研发、生产和销售。天风证券研报指,对于公司目前已有业务,预计公司2019-2021年净利润达到1.03、1.26、1.47亿港元。工业大麻新业务有望为公司带来新的业绩增量。鉴于公司传统业务稳定,工业大麻业务布局扎实、拓展迅速,维持“买入”评级。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.